Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Novartis Pharmaceuticals Corporation.

Advances In™: The Emerging Role of MET Inhibitors Across NSCLC Treatment

Release Date: June 30, 2020
Expiration Date: June 30, 2021

Activity Overview

This online educational activity is designed to provide expert interpretation of current and emerging data on the treatment of non–small cell lung cancer (NSCLC), with a forward-looking perspective on how the novel drug class of mesenchymal-epithelial transition (MET) inhibitors might impact clinical practice. The essentials of disease classification and molecular testing, clinical trial data, and dynamic treatment paradigms incorporating MET inhibition will be presented in a multimedia format, including a series of video interviews with expert thought leaders integrated within text-based modules.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Novartis Pharmaceuticals Corporation.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is directed toward medical oncologists and pulmonologists who treat patients with lung cancer. Pathologists, histologists, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of cancer will be invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Describe how an understanding of dysregulated MET signaling can inform rational therapeutic drug development designed to overcome resistance in advanced NSCLC
  • Discuss evidence concerning the efficacy and safety of emerging MET inhibition strategies under evaluation in early- and late-stage clinical trials
  • Consider the impact of recent clinical trial findings in the context of evolving treatment paradigms in the management of advanced forms of NSCLC

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Edward B. Garon, MD, MS
Edward B. Garon, MD, MS
Associate Professor
Department of Medicine, Division of Hematology/Oncology
Director of Thoracic Oncology
David Geffen School of Medicine at UCLA
Los Angeles, CA

Disclosures: Grant/Research Support: AZ, BMS, Merck, Eli Lilly, Genentech, Novartis, EMO Serono, lovance, Mirati, Neon, Dynavax. Consultant: Dracen, EMDO Serono, Novartis, GSK.

Roy S. Herbst, MD, PhD
Roy S. Herbst, MD, PhD
Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology, Yale University School of Medicine
Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital
Associate Cancer Center Director for Translational Research, Yale Cancer Center
Smilow Cancer Hospital at Yale New Haven
New Haven, CT

Disclosures: Grant/Research Support: AstraZeneca, Eli Lilly and Company, Genentech/Roche, Merck and Company. Consultant: AbbVie Pharmaceuticals, ARMO Biosciences, AstraZeneca, Biodesix, Bolt Biotherapeutics, Bristol Myers Squibb, Cybrexa Therapeutics, Eli Lilly and Company, EMD Serono, Genentech/Roche, Genmab, Halozyme, Heat Biologics, I-MAB Biopharma, Immunocore, Infinity Pharmaceuticals, Loxo Oncology, Merck and Company, Mirati Therapeutics, Nektar, Neon Therapeutics, NextCure, Novartis, Pfizer, Sanofi, Seattle Genetics, Shire Plc, Spectrum Pharmaceuticals, Symphogen, Takeda, Tesaro, Tocagen. Other Support, Board Member non-executive/ independent: Junshi Pharmaceuticals.

The staff Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By